Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047346 · ClinicalTrials.gov registry record · Phase 1
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
A Phase 1 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00047346 is a Phase 1 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants, below the 27-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00047346, a Phase 1 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of erlotinib in treating patients who have unresectable liver cancer and liver dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG erlotinib hydrochloride
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2002-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047346
The ClinicalTrials.gov registry entry for NCT00047346 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 27-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (11% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Advanced Adult Primary Liver Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00047346 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00047346 about?
NCT00047346 is a clinical study titled "Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction". Phase I trial to study the effectiveness of erlotinib in treating patients who have unresectable liver cancer and liver dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
What is the current status of trial NCT00047346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2002-08.
What conditions does trial NCT00047346 study?
This clinical trial studies the following conditions: Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Adult Primary Hepatocellular Carcinoma.
What interventions are being tested in trial NCT00047346?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00047346?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00047346 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Adult Primary Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
COMPLETED · Phase 1
-
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
COMPLETED · Phase 1
-
TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Advanced Adult Primary Liver Cancer
All registered trials for this condition
Localized Unresectable Adult Primary Liver Cancer
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.